The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma

Lisa M Rimsza, K. Campbell, W. S. Dalton, S. Salmon, G. Willcox, T. M. Grogan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The major vault protein (MVP), a ribonucleoprotein complex which mediates the transport of xenobiotic toxins, has been implicated in multidrug resistance (MDR) not mediated by p-glycoprotein (P-gp) or multidrug resistance related protein (MRP). We evaluated, via immunohistochemistry, the presence of MVP in plasma cells of myeloma patients. Among 73 patients registered with the Southwest Oncology Group (SWOG), 52 patients (74%) were positive for MVP. The presence of MVP and P-gp were significantly associated (p < 0.01). A univariate analysis of response versus MVP positivity showed borderline statistical significance (p = 0.043) with no association with OS or PFS. In particular, MVP positivity at first biopsy was associated with non-responsiveness to therapy (7/7 patients, 100%). MRP was not present in any of 23 samples tested. An increased proliferative rate (Ki-67 > 5%) was significantly associated with shorter OS (log rank p-value = 0.0002). The collective work indicates that MVP protein is common and abundant in myeloma with potential relevance to therapeutic response.

Original languageEnglish (US)
Pages (from-to)315-324
Number of pages10
JournalLeukemia and Lymphoma
Volume34
Issue number3-4
StatePublished - 1999
Externally publishedYes

Fingerprint

Multidrug Resistance-Associated Proteins
Multiple Myeloma
Glycoproteins
P-Glycoproteins
Ribonucleoproteins
Multiple Drug Resistance
Xenobiotics
Immunohistochemistry
major vault protein
Proteins

Keywords

  • Ki-67
  • LRP
  • Major vault protein
  • Multidrug-resistance
  • Multiple Myeloma
  • P-gp

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. / Rimsza, Lisa M; Campbell, K.; Dalton, W. S.; Salmon, S.; Willcox, G.; Grogan, T. M.

In: Leukemia and Lymphoma, Vol. 34, No. 3-4, 1999, p. 315-324.

Research output: Contribution to journalArticle

Rimsza, LM, Campbell, K, Dalton, WS, Salmon, S, Willcox, G & Grogan, TM 1999, 'The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma', Leukemia and Lymphoma, vol. 34, no. 3-4, pp. 315-324.
Rimsza, Lisa M ; Campbell, K. ; Dalton, W. S. ; Salmon, S. ; Willcox, G. ; Grogan, T. M. / The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. In: Leukemia and Lymphoma. 1999 ; Vol. 34, No. 3-4. pp. 315-324.
@article{37e1c726fda846f8a8a60ecf71097092,
title = "The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma",
abstract = "The major vault protein (MVP), a ribonucleoprotein complex which mediates the transport of xenobiotic toxins, has been implicated in multidrug resistance (MDR) not mediated by p-glycoprotein (P-gp) or multidrug resistance related protein (MRP). We evaluated, via immunohistochemistry, the presence of MVP in plasma cells of myeloma patients. Among 73 patients registered with the Southwest Oncology Group (SWOG), 52 patients (74{\%}) were positive for MVP. The presence of MVP and P-gp were significantly associated (p < 0.01). A univariate analysis of response versus MVP positivity showed borderline statistical significance (p = 0.043) with no association with OS or PFS. In particular, MVP positivity at first biopsy was associated with non-responsiveness to therapy (7/7 patients, 100{\%}). MRP was not present in any of 23 samples tested. An increased proliferative rate (Ki-67 > 5{\%}) was significantly associated with shorter OS (log rank p-value = 0.0002). The collective work indicates that MVP protein is common and abundant in myeloma with potential relevance to therapeutic response.",
keywords = "Ki-67, LRP, Major vault protein, Multidrug-resistance, Multiple Myeloma, P-gp",
author = "Rimsza, {Lisa M} and K. Campbell and Dalton, {W. S.} and S. Salmon and G. Willcox and Grogan, {T. M.}",
year = "1999",
language = "English (US)",
volume = "34",
pages = "315--324",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma

AU - Rimsza, Lisa M

AU - Campbell, K.

AU - Dalton, W. S.

AU - Salmon, S.

AU - Willcox, G.

AU - Grogan, T. M.

PY - 1999

Y1 - 1999

N2 - The major vault protein (MVP), a ribonucleoprotein complex which mediates the transport of xenobiotic toxins, has been implicated in multidrug resistance (MDR) not mediated by p-glycoprotein (P-gp) or multidrug resistance related protein (MRP). We evaluated, via immunohistochemistry, the presence of MVP in plasma cells of myeloma patients. Among 73 patients registered with the Southwest Oncology Group (SWOG), 52 patients (74%) were positive for MVP. The presence of MVP and P-gp were significantly associated (p < 0.01). A univariate analysis of response versus MVP positivity showed borderline statistical significance (p = 0.043) with no association with OS or PFS. In particular, MVP positivity at first biopsy was associated with non-responsiveness to therapy (7/7 patients, 100%). MRP was not present in any of 23 samples tested. An increased proliferative rate (Ki-67 > 5%) was significantly associated with shorter OS (log rank p-value = 0.0002). The collective work indicates that MVP protein is common and abundant in myeloma with potential relevance to therapeutic response.

AB - The major vault protein (MVP), a ribonucleoprotein complex which mediates the transport of xenobiotic toxins, has been implicated in multidrug resistance (MDR) not mediated by p-glycoprotein (P-gp) or multidrug resistance related protein (MRP). We evaluated, via immunohistochemistry, the presence of MVP in plasma cells of myeloma patients. Among 73 patients registered with the Southwest Oncology Group (SWOG), 52 patients (74%) were positive for MVP. The presence of MVP and P-gp were significantly associated (p < 0.01). A univariate analysis of response versus MVP positivity showed borderline statistical significance (p = 0.043) with no association with OS or PFS. In particular, MVP positivity at first biopsy was associated with non-responsiveness to therapy (7/7 patients, 100%). MRP was not present in any of 23 samples tested. An increased proliferative rate (Ki-67 > 5%) was significantly associated with shorter OS (log rank p-value = 0.0002). The collective work indicates that MVP protein is common and abundant in myeloma with potential relevance to therapeutic response.

KW - Ki-67

KW - LRP

KW - Major vault protein

KW - Multidrug-resistance

KW - Multiple Myeloma

KW - P-gp

UR - http://www.scopus.com/inward/record.url?scp=0032840591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032840591&partnerID=8YFLogxK

M3 - Article

C2 - 10439368

AN - SCOPUS:0032840591

VL - 34

SP - 315

EP - 324

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -